{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T10:17:52Z","timestamp":1791627472651,"version":"4.3.4"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["Project No. 2018YFC0115700"],"award-info":[{"award-number":["Project No. 2018YFC0115700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Background<\/jats:title>\n \n Heavy ion radiotherapy, such as carbon ion radiotherapy (CIRT), has multiple advantages over conventional photon therapy. Cisplatin, as a classic anti-tumor drugs, has been tested and discovered as a photon radiosensitizer in several cell lines, including head and neck squamous cell carcinoma (HNSCC). Hence, the aim of our study is to evaluate whether cisplatin can sensitize CIRT towards HNSCC cell lines\n in vitro<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Human nasopharyngeal carcinoma cell line CNE-2, human tongue squamous carcinoma cell line TCA 8113 and human hypopharynx squamous carcinoma cell line FADU were all irradiated with photon beam of 2, 4, 6, 8 Gy (physical dose) and carbon ion beam of 1, 2, 3, 4 Gy (physical dose) and treated with cisplatin. Cell survival was assessed by clonogenic survival assay.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n CIRT showed significantly stronger cytotoxic effect than standard photon radiotherapy. The relative biological effectiveness (RBE) of carbon ion beam at 10% survival (\n \n \n \n R<\/mml:mi>\n B<\/mml:mi>\n \n E<\/mml:mi>\n \n 10<\/mml:mn>\n <\/mml:mrow>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:inline-formula>\n ) was calculated 3.07 for CNE-2, 2.33 for TCA 8113 and 2.36 for FADU. Chemoradiotherapy (both photon radiotherapy and CIRT) was more effective than radiotherapy alone.\n In vitro<\/jats:italic>\n sensitizer enhancement ratios (SERs) of cisplatin in CNE-2, TCA 8113 and FA DU cell lines after photon irradiation were 1.33, 1.14 and 1.21, while after carbon ion irradiation were 1.02, 1.00 and 0.96, showed that cisplatin sensitized photon irradiation but showed no sensitization effect in carbon ion irradiation in all tested cell lines.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In conclusion, high linear energy transfer (LET) CIRT was more effective than photon irradiation to prevent the proliferation of HNSCC cell lines. Additional treatment with cisplatin could sensitize photon irradiation but showed no effect on carbon ion irradiation.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2023.896142","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T01:29:41Z","timestamp":1680571781000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["In vitro evaluation of photon and carbon ion radiotherapy in combination with cisplatin in head and neck squamous cell carcinoma cell lines"],"prefix":"10.3389","volume":"13","author":[{"given":"Xumeng","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangle","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiade Jay","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000446117","article-title":"Global epidemiology of head and neck cancers: A continuing challenge","volume":"91","author":"Gupta","year":"2016","journal-title":"Oncology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S229524","article-title":"Competing morbidities in advanced head and neck squamous cell carcinoma concurrent chemoradiotherapy: A strong implication of a multidisciplinary team approach","volume":"11","author":"Lazzari","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"vi7","DOI":"10.1093\/annonc\/mdi452","article-title":"Current clinical outcomes demand new treatment options for SCCHN","volume":"16","author":"Lefebvre","year":"2005","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23707","article-title":"et al: Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial","volume":"37","author":"Guo","year":"2015","journal-title":"Head Neck"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/srao.2003.50002","article-title":"The mechanism of action of radiosensitization of conventional chemotherapeutic agents","volume":"13","author":"Lawrence","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/09553008614551291","article-title":"Radiosensitization by cisplatin of RIF1 tumour cells in vitro","volume":"50","author":"Begg","year":"1986","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/bjc.1978.10","article-title":"Studies on cis-dichlorodiammineplatinum (II) as a radiosensitizer","volume":"3","author":"Alvarez","year":"1978","journal-title":"Br J Cancer Supplement"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7297","article-title":"Survival after definitive chemoradiotherapy with concurrent cisplatin or carboplatin for head and neck cancer","volume":"17","author":"Xiang","year":"2019","journal-title":"J Natl Compr Cancer Network"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/02841860310004364","article-title":"Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer--a review of their cooperation","volume":"42","author":"Marcu","year":"2003","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4236\/ijmpcero.2014.33019","article-title":"Carbon-ion beams efficiently induce cell killing in X-ray resistant human squamous tongue cancer cells","volume":"3","author":"Takahashi","year":"2014","journal-title":"Int J Med Physics Clin Eng Radiat Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ijrobp.2015.12.362","article-title":"Working group for pancreas c: Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic cancer","volume":"95","author":"Shinoto","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10281","article-title":"Carbon ion irradiation withstands cancer stem cells' migration invasion process in head and neck squamous cell carcinoma (HNSCC)","volume":"7","author":"Moncharmont","year":"2016","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.01.012","article-title":"et al: Different mechanisms of cell death in radiosensitive and radioresistant P53 mutated head and neck squamous cell carcinoma cell lines exposed to carbon ions and X-rays","volume":"74","author":"Maalouf","year":"2009","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S15997","article-title":"In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer","volume":"6","author":"Zhang","year":"2011","journal-title":"Int J Nanomedicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.radonc.2011.10.023","article-title":"Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo","volume":"104","author":"Lin","year":"2012","journal-title":"Radiother Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/s41467-017-01730-x","article-title":"et al: Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations","volume":"8","author":"Deng","year":"2017","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0278","article-title":"Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft","volume":"10","author":"Senra","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1667\/RR14984.1","article-title":"Dose-modifying factor of radiation therapy with concurrent cisplatin treatment in HPV-positive squamous cell carcinoma: A preclinical study","volume":"189","author":"Prevc","year":"2018","journal-title":"Radiat Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2012.06.006","article-title":"Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma","volume":"48","author":"Adachi","year":"2012","journal-title":"Oral Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10364","article-title":"Radiosensitization effects of curcumin plus cisplatin on non-small cell lung cancer A549 cells","volume":"18","author":"Cai","year":"2019","journal-title":"Oncol Lett"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/09553000601121108","article-title":"Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells","volume":"83","author":"Rave-Frank","year":"2007","journal-title":"Int J Radiat Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(81)90011-0","article-title":"Effect of cis-dichlorodiammine platinum II and X rays on mammalian cell survival","volume":"7","author":"Carde","year":"1981","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41598-020-58502-9","article-title":"Synergistic effect of cisplatin chemotherapy combined with fractionated radiotherapy regimen in HPV-positive and HPV-negative experimental pharyngeal squamous cell carcinoma","volume":"10","author":"Kranjc Brezar","year":"2020","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/0360-3016(90)90226-A","article-title":"Cisplatin and radiotion interaction probabilities and therapeutic possibilities","volume":"19","author":"Begg","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B30","doi-asserted-by":"publisher","first-page":"40588","DOI":"10.1038\/srep40588","article-title":"Mitotic catastrophe is a putative mechanism underlying the weak correlation between sensitivity to carbon ions and cisplatin","volume":"7","author":"Kobayashi","year":"2017","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/09553000802641151","article-title":"Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines","volume":"85","author":"Combs","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3109\/09553002.2013.791406","article-title":"Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines - does scheduling matter","volume":"89","author":"Harrabi","year":"2013","journal-title":"Int J Radiat Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3584","article-title":"Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo","volume":"6","author":"Sai","year":"2015","journal-title":"Oncotarget"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3892\/or.15.4.913","article-title":"Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation","volume":"15","author":"Kitabayashi","year":"2006","journal-title":"Oncol Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrv097","article-title":"S-phase-specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro","volume":"57","author":"Harrabi","year":"2016","journal-title":"J Radiat Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-8-260","article-title":"Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro","volume":"8","author":"Schlaich","year":"2013","journal-title":"Radiat Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12943-015-0429-7","article-title":"Carbon ion beam combined with cisplatin effectively disrupts triple negative breast cancer stem-like cells in vitro","volume":"14","author":"Sai","year":"2015","journal-title":"Mol Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23756","article-title":"Effects of carbon ion beam alone or in combination with cisplatin on malignant mesothelioma cells in vitro","volume":"9","author":"Sai","year":"2018","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1748-717X-7-9","article-title":"In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells","volume":"7","author":"Combs","year":"2012","journal-title":"Radiat Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrs010","article-title":"Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer","volume":"53","author":"Kuroda","year":"2012","journal-title":"J Radiat Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.17.1210","article-title":"Improved survival in stage III non-small-cell lung cancer seven-year follow-up of cancer and leukemia group b (CALGB) 8433 trial","volume":"88","author":"Dillman","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.12.046","article-title":"Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for stage III and IVa head-and-neck cancer","volume":"79","author":"Maguire","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010778","article-title":"Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis","volume":"97","author":"Lee","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1305","article-title":"Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1\/2 clinical trial (Protocol 1001)","volume":"7","author":"Okonogi","year":"2018","journal-title":"Cancer Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12244","article-title":"Long-term outcomes of carbon-ion radiotherapy for locally advanced squamous cell carcinoma of the uterine cervix","volume":"38","author":"Okonogi","year":"2018","journal-title":"Anticancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.12.013","article-title":"Results of carbon ion radiotherapy for head and neck cancer","volume":"103","author":"Mizoe","year":"2012","journal-title":"Radiother Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.896142\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T01:29:45Z","timestamp":1680571785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.896142\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":47,"alternative-id":["10.3389\/fonc.2023.896142"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.896142","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"article-number":"896142"}}